Advertisement

Allosteric Potentiators of Neuronal Nicotinic Cholinergic Receptors: Potential Treatments for Neurodegenerative Disorders

  • Emanuele Sher
  • Giovanna De Filippi
  • Tristan Baldwinson
  • Ruud Zwart
  • Kathy H. Pearson
  • Martin Lee
  • Louise Wallace
  • Gordon I. McPhie
  • Martine Keenan
  • Renee Emkey
  • Sean P. Hollinshead
  • Colin P. Dell
  • S. Richard Baker
  • J. Michael O’Neil
  • Lisa M. Broad
Part of the Advances in Behavioral Biology book series (ABBI, volume 57)

Keywords

Nicotinic Receptor Nicotinic Acetylcholine Receptor Gaba Release Human Neuroblastoma Cell Line nAChR Subtype 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

references

  1. Lindstrom J. The structures of neuronal nicotinic receptors. In: Clementi F, Fornasari D, Gotti C (eds) Neuronal Nicotinic Receptors, Handbook of Experimental Pharmacology, vol 144. New York: Springer, 2000, pp 101–162.Google Scholar
  2. McGehee DS, Role LW. Physiological diversity of nicotinic acetylcholine receptors expressed by vertebrate neurones. Annu Rev Physiol 1995;57:521–546.PubMedCrossRefGoogle Scholar
  3. Karlin A. Emerging structure of the nicotinic acetylcholine receptors. Nat Rev Neurosci 2002;3:102–114.PubMedCrossRefGoogle Scholar
  4. Celie PH, van Rossum-Fikkert SE, van Dijk W, et al. Nicotine and carbamylcholine binding to nicotinic acetylcholine receptors as studied in AChBP crystal structures. Neuron 2004;41:907–914.PubMedCrossRefGoogle Scholar
  5. Pereira EF, Hilmas C, Santos MD, et al. Unconventional ligands and modulators of nicotinic receptors. J Neurobiol 2002;53:479–500.PubMedCrossRefGoogle Scholar
  6. Mulle C, Lena C, Changeux JP. Potentiation of nicotinic receptor response by external calcium in rat central neurons. Neuron 1992;8:937–945.PubMedCrossRefGoogle Scholar
  7. Galzi JL, Bertrand S, Corringer PJ, et al. Identification of calcium binding sites that regulate potentiation of a neuronal nicotinic acetylcholine receptor. EMBO J 1996;15:5824–5832.PubMedGoogle Scholar
  8. Pereira EF, Alkondon M, Reinhardt S, et al. Physostigmine and galanthamine: probes for a novel binding site on the alpha 4 beta 2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells. J Pharmacol Exp Ther 1994;70:768–778.Google Scholar
  9. Zwart R, DeFilippi G, Broad LM, et al. 5-Hydroxyindole potentiates human α7 nicotinic receptor-mediated responses and enhances acetylcholine-induced glutamate release in cerebellar slices. Neuropharmacology 2002;43:374–384.PubMedCrossRefGoogle Scholar
  10. Kooyman AR, Van Hooft JA, Vijverberg HPM. 5-Hydroxyindole slows desensitization of 5-HT3 receptor-mediated ion current in N1E-115 neuroblastoma cells. Br J Pharmacol 1993;108:287–289.Google Scholar
  11. Krause RM, Buisson B, Bertrand S, et al. Ivermectin: a positive allosteric effector of the α7 neuronal nicotinic acetylcholine receptor. Mol Pharmacol 1998;53:283–294.PubMedGoogle Scholar
  12. Shan Q, Haddrill JL, Lynch JW. Ivermectin, an unconventional agonist of the glycine receptor chloride channel. J Biol Chem 2001;276:12556–12564.PubMedCrossRefGoogle Scholar
  13. Khakh BS, Proctor WR, Dunwiddle TV, et al. Allosteric control of gating and kinetics at P2X4 receptor channels. J Neurosci 1999;19:7289–7299.Google Scholar
  14. Curtis L, Buisson B, Bertrand S, Bertrand D. Potentiation of human α4β2 neuronal nicotinic acetylcholine receptor by estradiol. Mol Pharmacol 2002;61:127–135.PubMedCrossRefGoogle Scholar
  15. Astles PC, Baker S, Boot JR, et al. Recent progress in the development of subtype selective nicotinic acetylcholine receptor ligands. Curr Drug Targets CNS Neurol Disord 2002;1:337–348.PubMedCrossRefGoogle Scholar
  16. Broad LM, Zwart R, Pearson KH, et al. Identification and pharmacological profile of a new class of selective nicotinic acetylcholine receptor potentiators. J Pharmacol Exp Ther 2006;318:1108–1117.PubMedCrossRefGoogle Scholar
  17. Clementi F, Cabrini D, Gotti C, Sher E. Pharmacological characterization of cholinergic receptors in a human neuroblastoma cell line. J Neurochem 1986;47:291–297.PubMedCrossRefGoogle Scholar
  18. Sher E, Chen Y, Sharples TJW, et al. Physiological roles of neuronal nicotinic receptor subtypes: new insights on the nicotinic modulation of neurotransmitter release, synaptic transmission and plasticity. Curr Top Med Chem 2004;4:283–297.PubMedCrossRefGoogle Scholar
  19. Dani JA. Overview of nicotinic receptors and their roles in the central nervous system. Biol Psychiatry 2001;49:166–174.PubMedCrossRefGoogle Scholar
  20. Court J, Martin-Ruiz C, Piggott M, et al. Nicotinic receptor abnormalities in Alzheimer’s disease. Biol Psychiatry 2001;49:175–184.PubMedCrossRefGoogle Scholar
  21. Quik M, Kulak JM. Nicotine and nicotinic receptors; relevance to Parkinson's disease. Neurotoxicology 2002;23:581–594.PubMedCrossRefGoogle Scholar
  22. Levin ED, Rezvani AH. Development of nicotinic drug therapy for cognitive disorders. Eur J Pharmacol 2000;393:141–146.PubMedCrossRefGoogle Scholar
  23. Buccafusco JJ, Letchworth SR, Bencherif M, Lippiello PM. Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic discordance. Trends Pharmacol Sci 2005;26:352–360.PubMedCrossRefGoogle Scholar
  24. Kem WR. The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res 2000;113:169–181.PubMedCrossRefGoogle Scholar
  25. Lloyd GK, Williams M. Neuronal nicotinic acetylcholine receptors as novel drug targets. J Pharmacol Exp Ther 2000;2:461–467.Google Scholar
  26. Maelicke A, Schrattenholz A, Samochocki M, et al. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav Brain Res 2000;113:199–206.PubMedCrossRefGoogle Scholar
  27. Woodruff-Pak DS, Lander C, Geerts H. Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev 2002;8:405–426.PubMedCrossRefGoogle Scholar
  28. Samochocki M, Hoffle A, Fehrenbacher A, et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not muscarinic acetylchloline receptors. J Pharmacol Exp Ther 2003;305:1024–1036.PubMedCrossRefGoogle Scholar
  29. Moriguchi S, Marszalec W, Zhao X, et al. Mechanism of action of galantamine on N-methyl-d-aspartate receptors in rat cortical neurons. J Pharmacol Exp Ther 2004;310:933–942.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Emanuele Sher
    • 1
  • Giovanna De Filippi
  • Tristan Baldwinson
  • Ruud Zwart
  • Kathy H. Pearson
  • Martin Lee
  • Louise Wallace
  • Gordon I. McPhie
  • Martine Keenan
  • Renee Emkey
  • Sean P. Hollinshead
  • Colin P. Dell
  • S. Richard Baker
  • J. Michael O’Neil
  • Lisa M. Broad
  1. 1.Eli Lilly and Company, Lilly Research Centre, Erl Wood ManorWindleshamUK

Personalised recommendations